Skip to main content
World Cancer Day 2024 With Oncology Data Advisor
Keira Smith
Expert Analysis
In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular testing, clinical trial diversity, and patient advocacy worldwide.  
World Cancer Research Day With Samuel Kareff, MD, MPH; Maria Badillo, RN; Matthew Hadfield, DO; and Alankrita Taneja, MD
Keira Smith
Expert Analysis
In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share their passions for cancer research, discuss the recent and upcoming progress in their respective areas of study, and raise awareness for the tireless efforts being undertaken to advance cancer research.  
The Rise of Immunotherapy: Considerations to Ensure Optimal Management With Matthew Hadfield, DO
Keira Smith
Expert Analysis
In this Oncology Data Advisor Fellows Forum Interview, Dr. Matthew Hadfield, third-year Hematology/Oncology Fellow at Brown University, shares a comprehensive timeline of the history of immunotherapy and its emerging role in cancer treatment. Additionally, he shares considerations for the differential diagnosis of immunotherapy-related adverse events, timely management for providing optimal efficacy outcomes, and the importance of keeping immunotherapy-related toxicities on the radar for clinicians of all specialties and types of practice.  
Melphalan for Liver-Directed Treatment of Uveal Melanoma With Richard Carvajal, MD
Lyn Brook
Expert Analysis
Recently, the FDA approved melphalan for liver-directed treatment of uveal melanoma. In this interview, Oncology Data Advisor Editorial Board member Dr. Richard Carvajal, Deputy Physician-in-Chief and Director of Medical Oncology at Northwell Health Cancer Institute in New York, discusses the approval and the trial that led to it, as well as share ...
See, Hear, Feel: Exploring Cognitive Psychology and Emotional Intelligence in Medicine With Christine Ko, MD
Keira Smith
Expert Analysis
In this interview, Oncology Data Advisor® is joined by Dr. Christine Ko, Professor of Dermatology and Pathology at Yale University and host of the See, Hear, Feel podcast. Dr. Ko shares her passion for incorporating cognitive psychology and emotional intelligence into medical practice and explains how doing so can enhance patient encounters and care.  
Piloting Melanoma Research and Local Cancer Care: An Oncology Data Advisor® Editorial Board Spotlight Interview With Richard Carvajal, MD
Keira Smith
Expert Analysis
This interview is the first in a new series spotlighting the Oncology Data Advisor® Editorial Board, featuring Dr. Richard Carvajal, Director of Medical Oncology at Northwell Health Cancer Institute. Dr. Carvajal tells the story of how he became a melanoma researcher and shares his passions for developing targeted therapies for unique clinical subsets of melanoma and for providing high-quality cancer care for patients in their own neighborhoods.  
Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma With Shaheer Khan, DO
Keira Smith
Expert Analysis
Recently, Oncology Data Advisor spoke with Dr. Shaheer Khan, an Assistant Professor of Medicine at Columbia University Irving Medical Center, in honor of Skin Cancer Awareness Month. Dr. Khan shares the promising results of two recent trials of cemiplimab and pembrolizumab for cutaneous squamous cell carcinoma, explains future directions in the treatment of patients who are ineligible for immunotherapy, and offers advice for members of the multidisciplinary cancer care team who are treating patients with this disease.  
The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD
Keira Smith
Expert Analysis
Recently, the FDA granted approval to tebentafusp for the treatment of patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma, marking the first agent to be approved for this rare ocular malignancy. In this interview, Dr. Richard Carvajal, Associate Professor of Medicine at Columbia University Irving Medical Center and editorial board member of Oncology Data Advisor, discusses the practice-changing significance of the approval of tebentafusp and delves further into future directions in the development of treatments for uveal melanoma.